TPCW
AVXL icon

TD Private Client Wealth’s Anavex Life Sciences AVXL Stock Holding History

TD Private Client Wealth’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-33
Closed -$592 – 1173
2021
Q3 		$592 Hold
33
– – ﹤0.01% 1152
2021
Q2 		$754 Hold
33
– – ﹤0.01% 1143
2021
Q1 		$493 Buy
+33
New +$360 ﹤0.01% 1125

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Private Client Wealth's AVXL Position: Q4 2021 in Review

TD Private Client Wealth sold out of Anavex Life Sciences (AVXL) in Q4 2021, closing a stake of 33 shares — an estimated $592 sold.

TD Private Client Wealth first reported a position in AVXL in Q1 2021 and held it in 3 quarters. The position peaked at $754 in Q2 2021. 149 funds tracked by Wall St. Rank hold AVXL as of Q4 2021.

  • TD Private Client Wealth reported no remaining Anavex Life Sciences position as of Q4 2021 after selling out during the quarter.
  • TD Private Client Wealth sold 33 Anavex Life Sciences shares in Q4 2021, an estimated $592.
  • TD Private Client Wealth first reported a position in Anavex Life Sciences in Q1 2021 and held it in 3 quarters.
  • TD Private Client Wealth's Anavex Life Sciences position peaked at $754 in Q2 2021.
  • 149 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2021.

Based on TD Private Client Wealth's 13F filing for Q4 2021, filed 16 Aug 2024.